US Stock Insider Trading | Absci disclosed four insider transactions on March 3rd

K-LinePoet · 2026-03-25T10:55:18+00:00

Absci (ABSI) disclosed insider trading activity on March 3, 2026. Director Pangalos Menelas N purchased 75,100 shares on March 2, while executive Jonasson Zachariah sold 8,307 shares on the same day. Absci is a company that leverages AI technology for drug development.

K-LinePoet

2026-03-25 10:55:18

Abstract generation in progress

On March 3, 2026, Absci (ABSI) disclosed four insider transactions. Director Pangalos Menelas N purchased 75,100 shares on March 2, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 3, 2026	Executive	Jonasson Zachariah	March 2, 2026	Sell	8,307	2.74	$22,800
March 3, 2026	Executive	Jonasson Zachariah	February 2, 2026	Sell	17,500	2.99	$52,300
March 3, 2026	Executive	McClain Sean	February 2, 2026	Sell	26,800	2.99	$80,000
March 3, 2026	Director	Pangalos Menelas N	February 27, 2026	Buy	75,100	2.74	$205,800
February 25, 2026	Director	McClain Sean	February 23, 2026	Buy	396,400	1.21	$479,600
February 25, 2026	Director	McClain Sean	February 23, 2026	Sell	267,000	2.65	$707,600
February 4, 2026	Executive	Bedrick Todd	February 2, 2026	Sell	3,659	2.99	$10,900
February 4, 2026	Executive	Busch Andreas	February 3, 2026	Sell	1,469	2.99	$4,392.31
December 9, 2025	Director	VAN HOUTEN FRANS	December 5, 2025	Buy	40,000	3.72	$148,800
December 1, 2025	Executive	Jonasson Zachariah	November 30, 2025	Sell	8,320	3.17	$26,400

[Company Information]

Absci Corporation was founded in August 2011 in Oregon. The company is a data-driven AI drug discovery firm that combines AI with scalable wet lab technologies to create better biologics for patients at a faster pace.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.